Pharmaceutical Executive Daily: FDA Approves Braftovi

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.

In today’s Pharmaceutical Executive Daily, the FDA approves Braftovi for mutant metastatic colorectal cancer, Novo Nordisk and GSK announce major deal activity in a mergers and acquisitions roundup, and UK regulators confiscate thousands of doses of illegal weight-loss medicines.

The FDA has approved Braftovi for patients with BRAF V600E-mutant metastatic colorectal cancer. The decision expands treatment options in a genetically defined subset of colorectal cancer, reinforcing the continued momentum behind biomarker-driven oncology strategies and combination therapy approaches in advanced disease.

In deal news, Novo Nordisk has entered a $2 billion partnership with Vivtex, further strengthening its pipeline through external innovation. Meanwhile, GSK announced a $950 million acquisition of 35Pharma Inc., signaling continued appetite for targeted bolt-on acquisitions to expand specialty and pipeline assets. Together, the transactions reflect sustained strategic investment as large pharmaceutical companies seek to offset competitive pressures and future revenue gaps.

Finally, the Medicines and Healthcare products Regulatory Agency has confiscated approximately 2,000 doses of illegal weight-loss drugs in a recent enforcement action. The move underscores growing regulatory vigilance as demand for weight-management therapies surges and unauthorized or counterfeit products proliferate in both online and offline markets.

Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.